Zobrazeno 1 - 10
of 30
pro vyhledávání: '"J A, de Torres Mateos"'
Autor:
E, Sotelo Burillo, E, Martínez Cuenca, J A, Lorente Garín, J, Morote Robles, J, Bellmunt Molins, J A, de Torres Mateos
Publikováno v:
Actas urologicas espanolas. 23(7)
The extragonadal germ-cell tumors (EGGCT) represent 5% of all germ-cell tumors at presentation. Histologically, they are identical to testis germ cell tumors. They may arise in such sites as the mediastinum, retroperitoneal area, sacrococcygeal area,
Autor:
J, Morote Robles, C X, Raventós Busquet, J A, Lorente Gaín, G, Encabo Duro, I, de Torres Ramirez, M A, López Pacios, J A, de Torres Mateos
Publikováno v:
Actas urologicas espanolas. 23(2)
To analyze if free PSA percentage can help to predict a potential surgical failure (PSF) in patients undergoing radical prostatectomy.Analysis of serum PSA concentration and free PSA percentage in 92 patients undergoing retropubic radical prostatecto
Autor:
J, Bellmunt Molins, A, Ribas, J, Albanell, J A, Lorente Garín, J A, de Torres Mateos, J, Morote Robles, M A, López Palacios, J M, Banús Gassol, S, Casado Cobo, N, Eres, L A, Solé Calvo
Publikováno v:
Archivos espanoles de urologia. 49(5)
The combination of carboplatin, methotrexate and vinblastine (M-CAVI) is an active and well-tolerated regimen for patients with bladder cancer who are ineligible for cisplatin-based regimens. We have prospectively randomized patients with locally adv
Autor:
J, Morote Robles, C, Reig Ruiz, M A, López Pacios, J A, Lorente Garin, J A, de Torres Mateos, A, Soler Rosello
Publikováno v:
Actas urologicas espanolas. 18(1)
PSA concentrations were measured in 421 women. In a first group comprising 309 subjects, the assay was carried out with kits containing polyclonal antibodies (PPSA). In the second group with 112 women, the assays used kits containing polyclonal antib
Autor:
C, Reig Ruíz, J, Morote Robles, J A, Lorente Garín, J I, Idoipe Tomás, M A, López Pacios, J A, de Torres Mateos, A, Soler Roselló
Publikováno v:
Archivos espanoles de urologia. 46(9)
Patients on anticoagulant therapy may develop urologic complications, the most common being hematuria. Other less common but more severe complications are spontaneous hemorrhage arising from urological structures, as spontaneous perirenal hematoma, o
Autor:
J, Morote Robles, C, Reig Ruiz, J, Vila Barja, M A, López Pacios, J A, de Torres Mateos, A, Soler Roselló
Publikováno v:
Actas urologicas espanolas. 17(5)
Analysis of the evolution of 78 patients with hormonally-treated non-metastatic prostate cancer. During an average follow-up of 62.3 months, local clinical and metastatic progression in 14.1% and 7.7% cases, respectively, was observed. Overall, PSA d
Autor:
J, Morote Robles, C, Reig Ruiz, J, Vila Barja, J A, Lorente Garin, M A, López Pacios, J A, de Torres Mateos, A, Soler Roselló
Publikováno v:
Actas urologicas espanolas. 17(3)
The evolution of non-metastatic prostate cancer treated with hormonal therapy does not appear to be affected by the performance of a transurethral resection (TUR) as a measure to expedite the common urinary tract. Of 82 patients followed for an inter
Autor:
C, Reig Ruiz, J, Morote Robles, J, Sáenz de Cabezón Marti, J, Vila Barja, M A, López Pacios, J A, De Torres Mateos, A, Soler Roselló
Publikováno v:
Archivos espanoles de urologia. 45(7)
We report 10 cases of spontaneous perirenal hematoma that had been treated from 1974 to 1992. Retroperitoneal hemorrhage was secondary to renal disease in 7 cases, perirenal in 2 and extrarenal in 1. The etiology of the condition is analyzed in detai
Publikováno v:
Actas urologicas espanolas. 16(6)
Evaluation of results obtained in 70 hormone-treated patients with disseminated prostate cancer. Thirty-six of them were treated via orchiectomy and 34 received also flutamide. Initial objective response rates were 47% in the monotherapy group versus
Publikováno v:
Actas urologicas espanolas. 16(5)
Eight patients with prostate adenoma and high surgical risk were given leuprolide in depot. Prostate volume decreased by 44.7% after 3 months of treatment and by 58.9% at six months. Two of the 7 patients were resident vesical catheter carriers, 28%